TG Therapeutics (NASDAQ:TGTX - Get Free Report) was upgraded by equities research analysts at The Goldman Sachs Group to a "hold" rating in a research note issued to investors on Thursday, MarketBeat Ratings reports. The brokerage currently has a $37.00 price target on the biopharmaceutical company's stock. The Goldman Sachs Group's price objective indicates a potential downside of 1.78% from the company's previous close.
TG Therapeutics Stock Performance
TGTX opened at $37.67 on Thursday. The company has a debt-to-equity ratio of 1.03, a quick ratio of 3.04 and a current ratio of 4.02. The company has a market cap of $5.98 billion, a PE ratio of 156.96 and a beta of 1.91. The stock has a 50-day moving average of $36.18 and a 200-day moving average of $35.25. TG Therapeutics has a 52-week low of $16.65 and a 52-week high of $46.48.
TG Therapeutics (NASDAQ:TGTX - Get Free Report) last posted its earnings results on Wednesday, May 7th. The biopharmaceutical company reported $0.03 earnings per share for the quarter, missing the consensus estimate of $0.19 by ($0.16). TG Therapeutics had a return on equity of 18.88% and a net margin of 10.13%. The company had revenue of $120.86 million during the quarter, compared to analyst estimates of $117.07 million. During the same quarter last year, the firm posted ($0.07) earnings per share. The firm's revenue for the quarter was up 90.4% compared to the same quarter last year. As a group, equities research analysts forecast that TG Therapeutics will post 0.08 earnings per share for the current fiscal year.
Insider Transactions at TG Therapeutics
In related news, Director Yann Echelard sold 10,000 shares of TG Therapeutics stock in a transaction on Friday, June 13th. The shares were sold at an average price of $36.94, for a total value of $369,400.00. Following the transaction, the director owned 228,816 shares in the company, valued at $8,452,463.04. This trade represents a 4.19% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Insiders own 10.64% of the company's stock.
Institutional Investors Weigh In On TG Therapeutics
A number of hedge funds have recently bought and sold shares of the company. CWM LLC increased its stake in shares of TG Therapeutics by 16.2% in the first quarter. CWM LLC now owns 2,085 shares of the biopharmaceutical company's stock worth $82,000 after purchasing an additional 290 shares during the period. Arizona State Retirement System increased its position in TG Therapeutics by 0.9% in the 4th quarter. Arizona State Retirement System now owns 42,639 shares of the biopharmaceutical company's stock worth $1,283,000 after buying an additional 364 shares during the period. Golden State Wealth Management LLC lifted its holdings in shares of TG Therapeutics by 100.0% during the first quarter. Golden State Wealth Management LLC now owns 866 shares of the biopharmaceutical company's stock worth $34,000 after buying an additional 433 shares during the last quarter. Summit Investment Advisors Inc. boosted its position in shares of TG Therapeutics by 3.3% in the fourth quarter. Summit Investment Advisors Inc. now owns 14,606 shares of the biopharmaceutical company's stock valued at $440,000 after acquiring an additional 463 shares during the period. Finally, Smartleaf Asset Management LLC grew its stake in shares of TG Therapeutics by 26.8% in the first quarter. Smartleaf Asset Management LLC now owns 2,416 shares of the biopharmaceutical company's stock worth $96,000 after acquiring an additional 511 shares during the last quarter. 58.58% of the stock is currently owned by institutional investors.
About TG Therapeutics
(
Get Free Report)
TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.
Further Reading
Before you consider TG Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and TG Therapeutics wasn't on the list.
While TG Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for July 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
